Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434746
Status:
COMPLETED
Last Update Posted:
2009-07-10
First Post:
2007-02-09
Brief Title:
Study of the Safety Tolerability PK and PD of ILV-094 Administered IV or SC to Healthy Subjects
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
Ascending Multiple Dose Study of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of ILV-094 Administered IV and One Dose of SC Administered to Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and tolerability of ascending single IV doses of ILV-094 an investigational drug and one SC dose of ILV-094 in healthy subjects
Detailed Description:
This is a randomized double-blind placebo-controlled inpatientoutpatient sequential-group study of ascending single IV doses of ILV-094 administered to healthy Japanese male subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None